The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Mathew Maurer, M.D. is a General Internist and Geriatric Cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Centre, Vagelos College of Physicians & Surgeons, where he directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). He is also a member of the Advanced Cardiac Care Centre at New York Presbyterian Hospital – Columbia Campus.
Dr. Maurer has published over 300 articles, including peer-reviewed manuscripts, reviews, and book chapters. He was chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organisation dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the steering committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy.
Throughout his career, Dr. Maurer has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine, in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately affect older adults.
Department of Cardiology of Hospital Universitario Puerta de Hierro, Madrid, Spain
Pablo García-Pavia, M.D. directs the Heart Failure and Inherited Cardiac Diseases Unit at the Department of Cardiology of Hospital Universitario Puerta de Hierro. This unit is designed by the Spanish Ministry of Health as a national reference unit (CSUR) for inherited cardiovascular diseases and by the European Commission as a European reference centre for rare and complex cardiovascular diseases.
In addition to his work at the hospital, Dr. García-Pavia is also a research professor at the Spanish National Research centre (CNIC) and the leader of the Inherited Cardiac Disease Programme at the CIBERCV, the Spanish collaborative research infrastructure that joins the 40 leading Spanish cardiovascular research groups. Since 2021 is also associate editor of Revista Española de Cardiología. He has published >200 articles in peer-reviewed journals including European Heart Journal, J Am Coll Cardiol, Circulation, Nature Communications, Nature Medicine and Lancet, and has led the 2021 ESC position paper on diagnosis and treatment of cardiac amyloidosis.
Royal Free Hospital, London, UK
Marianna Fontana, M.D., Ph.D., FRCP, is Professor of Cardiology and is an Honorary Consultant Cardiologist at the Royal Free Hospital, University College London, where she is Director of the UCL Cardiac MRI unit, deputy Head of Centre for Amyloidosis and deputy clinical lead of the National Amyloidosis Centre.
Prof. Fontana obtained her M.D. and qualifications as a cardiologist at the University of Pisa in 2011. In 2012 she obtained a BHF Clinical Research Training Fellowship to undertake a Ph.D. at UCL which focused on CMR in cardiac amyloidosis. In 2015 she became Senior Lecturer at UCL, Honorary Consultant Cardiologist and Director of the UCL CMR unit at the Royal Free Hospital, which she founded. In 2018 she was awarded an Intermediate Clinical Fellowship by the BHF. She was appointed deputy Head of Centre for Amyloidosis and Acute Phase Proteins and deputy clinical lead of the National Amyloidosis Centre in 2019. She took up the chair of Cardiology at UCL in 2020.
Prof. Fontana’s major clinical and research interests are in the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies: Imaging and drugs. She lectures widely in the UK and internationally on amyloidosis and organises many multi-professional educational events. She is on the board of trustees of SCMR and chair of the Education Committee for the society. She advises industry at all stages in the lifecycle of innovative products that can help improve the life-expectancy and quality of life of patients with amyloidosis. She is the recipient of numerous awards, including the Michael Davies Early Career Award in 2021 and the BHF Fellow of the year award in 2022. She has co-authored 217 peer reviewed publications with >13700 citations (h-index 64).